

Stellingen behorende bij het proefschrift

Type I Interferons in Primary Sjögren's Syndrome: *Assays and pathophysiological mechanisms*

Erika Huijser

1. The Myxovirus resistance protein 1-immunoassay is a reliable, cheap and fast alternative for blood type I interferon-stimulated gene expression analysis.
(Dit proefschrift)
2. Circulating interferon- α 2 in primary Sjögren's syndrome associates with disease-relevant serological parameters, hydroxychloroquine treatment and systemic disease manifestations.
(Dit proefschrift)
3. Monocytes and plasmacytoid dendritic cells from patients with primary Sjögren's syndrome are hyperresponsive to stimulation of the STING pathway.
(Dit proefschrift)
4. Nucleic acid-sensing pathways, trained immunity and cellular metabolism are all involved in type I interferon pathway activation in primary Sjögren's syndrome.
(Dit proefschrift)
5. Metabolic intervention is a novel treatment strategy to limit type I interferon pathway activation in primary Sjögren's syndrome.
(Dit proefschrift)
6. Sjögren's syndrome should henceforth be known as Sjögren disease.
(Baer AN and Hammitt KM. Arthr Rheum 2021; 73 (7):1347-1348 en Cottin V. Arthr Rheum 2021; 74 (2):366-367)
7. Prolonged interferon responses during persistent viral infections and obesogenesis underlie reciprocal causality between obesity and higher susceptibility of obese individuals to viral infections.
(Tian Y, et al. Biomolecules 2019; 9 (11): 726)
8. β -1,3-Glucans are natural molecules that can significantly improve human health.
(Vetvicka V, et al. Molecules 2019; 24 (7): 1251)
9. With aging, intensity and duration of innate inflammatory responses increase, rendering older individuals susceptible to tissue-damaging immunity and inflammatory disease.
(Weyand CM and Goronzy JJ. Ann Am Thorac Soc. 2016; 13 (Suppl 5): S422-S428)
10. The placebo response is an important contributor to the overall treatment effect and should be embraced in both clinical trials and practice for its potential benefits to patients.
(Haflíðadóttir, SH, et al. Trials 2021; 22 (1): 493)
11. Everything should be made as simple as possible, but not simpler.
(Toegeschreven aan Albert Einstein)